MC
KPTI icon

Moors & Cabot’s Karyopharm Therapeutics KPTI Stock Holding History

Moors & Cabot’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-813
Closed -$47.5K – 885
2023
Q1 		$47.5K Hold
813
– – ﹤0.01% 824
2022
Q4 		$41.5K Sell
813
-597
-42% -$41.4K ﹤0.01% 820
2022
Q3 		$115K Hold
1,410
– – 0.01% 753
2022
Q2 		$95K Sell
1,410
-27
-2% -$2.48K 0.01% 756
2022
Q1 		$159K Hold
1,437
– – 0.01% 787
2021
Q4 		$139K Buy
1,437
+27
+2% +$2.69K 0.01% 800
2021
Q3 		$123K Buy
1,410
+167
+13% +$17.3K 0.01% 789
2021
Q2 		$192K Sell
1,243
-20
-2% -$2.9K 0.01% 739
2021
Q1 		$199K Buy
1,263
+280
+28% +$59K 0.02% 690
2020
Q4 		$226K Buy
+983
New +$228K 0.02% 610

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Moors & Cabot's KPTI Position: Q2 2023 in Review

Moors & Cabot sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 813 shares — an estimated $47.5K sold.

Moors & Cabot first reported a position in KPTI in Q4 2020 and held it in 10 quarters. The position peaked at $226K in Q4 2020. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

  • Moors & Cabot reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Moors & Cabot sold 813 Karyopharm Therapeutics shares in Q2 2023, an estimated $47.5K.
  • Moors & Cabot first reported a position in Karyopharm Therapeutics in Q4 2020 and held it in 10 quarters.
  • Moors & Cabot's Karyopharm Therapeutics position peaked at $226K in Q4 2020.
  • 137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Moors & Cabot's 13F filing for Q2 2023, filed 10 Aug 2023.